ERAS · Erasca, Inc.
The AI's read
The early results show tumor responses in pancreatic and lung cancer patients, including people whose cancer had already been treated. Most patients stayed on treatment, and the company reported no treatment stops from side effects at the 32 mg dose. These findings support testing ERAS-0015 in a larger pancreatic cancer trial sooner. ERAS-4001 also showed early activity and may be tested alongside ERAS-0015. The evidence is still from Phase 1 studies, and the ERAS-0015 combinations have not yet reported efficacy data. Even so, the response results and reported safety support a positive reading.